Download Report Overview Despite frequent involvement with payers for the approval of biologics/JAKs in RA, rheumatologists report that their use is heavily impacted by the negative reimbursement and access environment, according to a recent report from Spherix Global Insights. August…
Download Report Overview At nearly six months post launch, three-quarters of US rheumatologists report having prescribed Cosentyx, a significant increase from the 24% who reported use at one month post-launch, according to a recent report from Spherix Global Insights. August…
Download Report Overview August 1, 2016 – Cambridge, MA- In the Q2 update of RealTime Dynamix™: Multiple Sclerosis, roughly one-quarter of the respondents reported increased payer restrictions for Teva’s Copaxone while restrictions have eased somewhat for Sandoz’s Glatopa, Novartis’ Extavia…
Download Report Overview At just over one month post launch, one-third of dermatologists report having prescribed Eli Lilly’s IL-17 inhibitor, Taltz, according to a recent report from Spherix Global Insights. July 26, 2016 – Cambridge, Massachusetts. At approximately six weeks…
The sixth monthly update on the launch of Veltassa and the evolution of the Hyperkalemia market provided by 101 Nephrologists. Download Report Overview About Spherix Global Insights Spherix Global Insights is a newly established business intelligence and market research company…
Monthly report covering the dialysis and chronic kidney disease market for ESAs and IV Iron. Additional insight on the development pipeline including receptivity to biosimilar ESAs and growing awareness of a novel class of anemia agents, the HIF-PH inhibitors. n=104…